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Abstract 
Objectives: This study aims to examine the efficacy of the Unified Protocol for Transdiagnostic 
Treatment of Emotional Disorders (UP) for individuals diagnosed with a depressive disorder. 
Method: Participants included 44 adults who met criteria for major depressive disorder, persistent 
depressive disorder, or another specified depressive disorder according to the Anxiety Disorder 
Interview Schedule (ADIS). These individuals represent a subset of patients from a larger clinical 
trial comparing the UP to single-disorder protocols (SDPs) for discrete anxiety disorders and a 
waitlist control (WLC) condition (Barlow et al., 2017); inclusion criteria for the parent study 
required participants to have a principal anxiety disorder. Results: Significant reductions in 
depressive symptoms were observed within the UP condition across clinician-rated and self-report 
measures of depression from baseline to post-treatment, as well as to the 12-month follow-up 
assessment. Compared to the WLC group, individuals in the UP condition demonstrated 
significantly lower levels on our continuous, clinician-rated measure of depressive symptoms at 
post-treatment. There were no differences between the UP and SDP conditions on depressive 
symptoms at post-treatment or at the 12-month follow-up timepoint. Conclusions: In this 
exploratory set of analyses, the UP evidenced efficacy for reduction of depressive symptoms, 
adding to the growing support for its utility in treating depression.  
Keywords: Unified Protocol, depression, transdiagnostic treatment  
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Treating Depression with the Unified Protocol: Results from a Randomized-Controlled Trial 
The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders (UP) 
(Barlow et al., 2011; Barlow et al., 2018) is an emotion-focused, cognitive-behavioral treatment 
designed to target core temperamental factors that underlie the development and maintenance of 
anxiety, depressive, and related disorders (i.e., emotional disorders; Bullis, Boettcher, Sauer-
Zavala, Farchione, & Barlow, 2019). These core factors include the propensity to experience 
frequent and intense negative affect, coupled with aversive reactions to emotional experiences 
when they occur (Barlow et al., 2014). The UP aims to reduce both the perception of negative 
affect as intolerable, as well as the avoidant coping strategies that result from these beliefs 
(Farchione et al., 2012). Importantly, this transdiagnostic framework may have advantages for 
the dissemination of evidence-based treatment. By emphasizing the shared mechanisms that 
underlie emotional disorders, rather than surface-level symptoms of specific disorders (e.g., 
panic, worry, social evaluation concerns, low mood), the UP has the potential to reduce burdens 
associated with training clinicians in many “diagnosis-specific” treatments; indeed, the UP 
represents a single protocol that can be flexibly used to target a broad range of comorbid 
conditions (e.g., Barlow et al., 2017).  
To date, the majority of efficacy data for the UP exist for individuals with anxiety 
disorders. Initial findings suggest that the UP results in significant improvement for symptoms of 
anxiety and depression in individuals with heterogenous anxiety disorders (Ellard et al., 2010; 
Farchione et al., 2012). Recently, in a large randomized controlled trial (RCT), Barlow and 
colleagues (2017) demonstrated that the UP resulted in equivalent symptom reduction for 
principal anxiety disorders as gold-standard single-disorder cognitive-behavioral protocol (SDP) 
explicitly developed to target each individual condition (Barlow et al., 2017); further, those in 
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the UP condition were more likely to remain in treatment longer than individuals in SDPs 
(Barlow et al., 2017).  
Applicability of the UP for depression  
 Though the UP has been most widely studied for anxiety disorders, converging theory 
and empirical evidence also indicate the promise of using this transdiagnostic approach to treat 
depression. Depressive disorders are highly comorbid with anxiety disorders (e.g., Brown & 
Barlow, 1992; Brown et al., 2001; Fava et al., 2000; Kessler et al., 1996), and researchers have 
theorized that shared vulnerabilities underlying depressive and anxiety disorders may be the 
reason for these high comorbidity rates (Andrews, 1996; Andrews, Stewart, Morris-Yates, Holt, 
& Henderson, 1990; Barlow et al., 2014). Indeed, empirical work supports the notion that 
neuroticism accounts for substantial variation in emotional disorders (e.g., Brown, Chorpita, & 
Barlow, 1998; Brown, 2007; Brown & Barlow, 2009; Griffiths et al., 2010; Kasch, Rottenberg, 
Arnow, & Gotlib, 2002; Kessler et al., 2011), and that this trait is elevated in individuals with 
MDD (Brown & Rosellini, 2011; Clark & Watson, 1991). As noted above, the transdiagnostic 
UP was specifically designed to target neuroticism, and thus, should be applicable across all 
disorders (including multiple comorbidities and symptoms) for which this trait plays a key role. 
Given that depression is highly prevalent, affecting 7% of the population (Brody, Pratt, & 
Hughes, 2018), and is associated with significant societal costs (Greenberg, Fournier, Sisitsky, 
Pike, & Kessler, 2015), it is necessary to continue to establish effective treatments for this 
condition. 
The core treatment components of the UP are highly relevant to depression. Briefly, 
intense and frequent negative affect (e.g., sadness, guilt, anger) and maladaptive, avoidant 
reactions to negative affect (e.g., social withdrawal, hypersomnia) characterize depression; as 
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previously noted, intense and frequent negative affect and aversive responding to negative affect 
are the UP’s primary (transdiagnostic) intervention targets. Furthermore, the UP also shares 
many key therapeutic strategies with extant empirically supported interventions for depression. 
For example, the first module incorporates motivational interviewing techniques that have been 
shown to improve treatment for individuals with depressive disorders (Keeley et al., 2016). 
Additionally, the second and third UP modules focus on cultivating a more objective, approach-
oriented stance toward emotions - akin to mindfulness- and acceptance-based approaches for 
depression (Segal, Williams, & Teasdale, 2002; Goldberg et al., 2018). The UP’s fourth module 
focuses on identifying automatic appraisal patterns and teaching cognitive reappraisal strategies 
to generate alternative cognitions, similar to traditional cognitive and cognitive-behavioral 
treatments for depression, while continuing to emphasize nonjudgmental awareness of one’s 
thoughts. In the UP’s “behavioral” module (the fifth module), like existing behavioral activation 
treatments for depression, patients practice identifying and modifying maladaptive, avoidant 
responses (e.g., inactivity, withdrawal) with specific, approach-oriented behaviors. Last, the sixth 
and seventh modules consist of systematic exposure exercises, in line with the many cognitive-
behavioral treatment protocols for depression that incorporate behavioral experiments as a key 
procedure.   
Prior evidence of the UP for depression 
 
 Preliminary empirical support of the UP for patients with unipolar depressive disorders 
comes from single-case and case studies, as well as small open-label and controlled trials of 
patients with co-occurring depressive disorders (and in some cases, principal MDD). For 
example, Boswell and colleagues (2014) reported on changes in symptoms and putative 
mechanisms of change over the course of UP treatment in a 64-year-old female with a principal 
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diagnosis of MDD, along with recurrent and co-occurring generalized anxiety disorder (GAD). 
Several additional case studies of individual patients with MDD who were treated with the UP 
have additionally shown clinically significant or reliable changes in self-reported depressive 
symptoms (Boswell & Bugatti, 2016; Boswell, Conklin, Oswald, & Bugatti, 2018; Farchione, 
Boswell, & Wilner, 2017; Hague, Scott, & Kellett, 2015). 
 In one of the first trials of the UP for patients with anxiety (N = 18, n = 3 of whom had 
comorbid depression), significant, moderate effects of the UP on clinician-rated depressive 
symptoms were observed in the overall sample (Ellard, Fairholme, Boisseau, Farchione, & 
Barlow, 2010). Though reductions in clinician-rated and self-report indicators of scores of 
depressive disorder severity were not statistically significant, the three patients who met criteria 
for a depressive disorder at baseline were all classified as “responders” (for their depressive 
disorder) at six-month follow-up. In a later open trial of the UP in Japan for adults with unipolar 
depression or anxiety (53% had principal depression), medium to large, significant reductions in 
depression were shown (Ito et al., 2016). Similar results were observed when the UP was 
delivered in group format in the Spanish public health system (Osma, Castellano, Crespo, & 
García-Palacios; 2015) In the first randomized, waitlist-controlled trial of the UP for adults with 
anxiety disorders (N = 37), 6 of 9 patients with a co-occurring depressive disorder no longer met 
criteria for depression at post-treatment, and at a six-month follow-up, 8 of 9 patients no longer 
met depressive disorder criteria (Farchione et al., 2012); large, statistically significant effect sizes 
for both clinician-rated and self-report measures of depression favored the UP. Similar results, 
favoring the UP versus a waitlist control condition, have also been found in a sample of patients 
(N = 29) with bipolar I or II experiencing a depressive episode (Ellard et al., 2017).  
Applicability and preliminary evidence for suicidal ideation 
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 As one of the nine symptoms of MDD (American Psychiatric Association, 2013), suicidal 
ideation may also be effectively targeted with the UP. As detailed in Bentley and colleagues 
(2017b), leading theoretical models point to the experience of intense negative affect as a key 
factor in the development and maintenance of suicidal thoughts and behaviors (e.g., Baumeister, 
1990; Beck, 1986; Joiner, 2005; Linehan 1993; Shneidman, 1993); indeed, neuroticism is 
associated with suicidal ideation even when adjusting for comorbid clinical disorders (e.g., 
Handley et al., 2012; Mandelli et al., 2015; Rappaport et al., 2017). Additionally, clinical 
observation (e.g., O’Connor, 2003; Selby, Anestis, & Joiner, 2007) and initial empirical support 
(e.g., Kleiman et al., 2018) suggest that suicidal thoughts and behaviors may serve similar 
functions to the aversive, avoidant reactions to negative affect that maintain emotional disorders. 
Whereas contemplating ending one’s life to relieve or escape intense emotional pain (or making 
a suicide plan or engaging in suicidal behavior) may provide some short-term relief from 
extremely distressing emotional states or comfort (e.g., Crane et al., 2014), these behaviors are 
unlikely to lead to long-term relief and may even worsen negative emotions over time (e.g., 
Crowell, Derbridge, & Beauchaine, 2014). Last, ample research has demonstrated that suicidal 
ideation and emotional disorders frequently co-occur (e.g., Nock, Hwang, Sampson, & Kessler, 
2010; Nock et al., 2009; Zimmerman et al., 2014). Pilot studies exploring the utility of the UP for 
addressing suicidal thoughts and behaviors have demonstrated that this approach is feasible, 
acceptable to patients, and is associated with promising improvements (Bentley et al., 2017a).  
The present study 
 
The present study is a secondary analysis of a recently completed clinical equivalency 
trial comparing the UP to gold-standard cognitive-behavioral protocols designed to target a 
single discrete anxiety diagnosis (i.e., SDP), along with a waitlist control (WLC) condition 
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(Barlow et al., 2017). We previously described changes in clinician-rated and self-reported 
depressive symptoms for all patients (i.e., with and without a co-occurring depressive disorder) 
in the UP condition (N = 88) and observed significant differences at post-treatment favoring the 
UP in comparison to the WLC, and non-significant differences compared to the SDPs (Barlow et 
al., 2017).  
Here we expand upon previous findings by exploring the effects of the UP on depression 
in individuals with principal anxiety disorders who also met criteria for a unipolar depressive 
disorder. The subset of 44 patients meeting this criterion were drawn from the larger trial, 
representing the largest sample of patients with a depressive disorder included in a randomized 
UP trial to date. Specifically, we explore changes in depressive symptoms for the individuals 
with a comorbid unipolar depressive disorder who received the UP (n = 17) from pre- to post-
treatment and 12-month follow-up. Additionally, we evaluate whether levels of depression 
between individuals treated with UP versus those in the waitlist condition (n = 12) are 
significantly different at pre-treatment and post-treatment. We also compare levels of depression 
between the UP and SDP (n = 15) conditions at pre- and post-treatment, along with at the 6-
month follow-up. Finally, as an additional exploratory aim, we also explore changes in suicidal 
ideation during across available study timepoints for each condition. 
Method 
Participants 
Treatment-seeking participants from the community were recruited from a large, 
university-based community mental health center at Boston University. English-speaking adults 
with a principal (most interfering and severe) diagnosis of panic disorder (PD), generalized 
anxiety disorder (GAD), obsessive-compulsive disorder (OCD), or social anxiety disorder 
UNIFIED PROTOCOL FOR DEPRESSION 9 
(SOC), as assessed by the Anxiety Disorders Interview Schedule (ADIS; Brown & Barlow, 
2014; Brown, Barlow, & DiNardo, 1994), were eligible. In line with long standing procedures 
for clinical trials at our Center, individuals taking psychotropic medications were required to 
have been stable on the same dose for at least six weeks prior to enrollment, and to maintain 
these medications and dosages throughout the treatment. Exclusion criteria consisted primarily of 
conditions that required prioritization for immediate or simultaneous treatment that could interact 
with the study treatment. For more information, see Barlow et al., (2017).  
A total of 223 participants in the parent clinical trial (see Barlow et al, 2017) were 
randomized in a 2:2:1 allocation ratio to the following three conditions: UP, SDP1, and waitlist 
control (WLC). Given our goal of evaluating the UP’s effect on depressive symptoms, the 
present study includes the subset of participants who reached clinical severity ratings (CSR) of 
four or higher for a depressive disorder at baseline (n = 44), reflecting a clinical level of 
distress/impairment associated with their depressive disorder specifically (see diagnostic 
assessment section below: Brown & Barlow, 2014; DiNardo et al., 1994). The sample was 
predominantly white (77.27%), female (47.73%), with a mean age of 33.36 (SD = 11.71) and had 
attended at least some college (93.18%)  
Procedures 
Patients in the UP and SDP conditions completed a 16-session acute treatment phase, 
followed by a 12-month follow-up phase; of note, patients with principal PD/A received 12 
sessions to match the treatment length recommendations for the SDP condition (see Study 
Intervention section for full details on each SDP). Patients in the WLC condition completed 16-
 
1 Patients assigned to this condition received a manualized, single diagnosis protocol that was associated with their 
principal diagnosis. For example, patients assigned to this condition with PD/A received Mastery of Your Anxiety 
and Panic (Barlow & Craske, 2007), whereas patients with GAD received Mastery of Your Anxiety and Worry (Craske 
& Barlow, 2006). 
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week assessment-only phase after which their study participation was completed; WLC patients 
did not participate in the follow-up phase. In the context of the present study, participants in all 
conditions completed self-report questionnaires and clinician-rated assessments at pre- and post-
treatment; participants in the UP and SDP conditions were also assessed at the 12-month follow-
up time-point. Clinician rated assessments were conducted by independent evaluators were 
trained to reliability on study instruments and were blinded to study condition. All procedures 
were approved by Boston University’s Institutional Review Board and patients provided their 
informed consent before participating. 
Study Interventions 
The UP was delivered in accordance with the published therapist guide (Barlow et al., 
2011) and client workbook (Barlow, Ellard, et al., 2011). The UP consists of five core treatment 
modules: 1) Mindful Emotion Awareness; 2) Cognitive Flexibility; 3) Countering Emotional 
Behaviors; 4) Awareness and Tolerance of Physical Sensations; and 5) Emotion Exposures. 
Sessions for patients with GAD, PD/A, and SOC were 60 minutes in duration, whereas patients 
with OCD received 90-minute sessions to correspond to the length recommendations made by 
the SDP for this disorder (see below for full information about each SDP). 
The SDP treatment protocols adopted in the present study included: Mastery of Anxiety 
and Panic – 4th edition (MAP-IV; Craske & Barlow, 2006); Treating Your OCD with Exposure 
and Response (Ritual) Prevention Therapy – 2nd edition  (ERP-II; Foa, Yadin, & Lichner, 2012); 
Mastery of Anxiety and Worry – 2nd edition (MAW-II; Zinbarg, Craske, & Barlow, 2006); and 
Managing Social Anxiety: A Cognitive-Behavioral Therapy Approach – 2nd edition (MSA-II; 
Hope, Heimberg, & Turk, 2010). As noted previously, treatment consisted of 16 sessions, each 
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60-minutes in duration, with the exception of the OCD intervention (90-minute session) and the 
PD/A protocol (12 sessions). 
Therapists and Treatment Integrity 
Study therapists were doctoral students in clinical psychology, postdoctoral fellows, and 
licensed clinical psychologists with training and certification in the treatment protocols utilized 
(Barlow, Gorman, Shear, & Woods, 2000). For both the UP condition and the SDPs, expert 
raters associated with the development of each treatment provided an overall competence rating 
for 20% of study sessions; these ratings incorporated adherence to a checklist of topics to be 
covered in each session, along with basic therapeutic skills (e.g., built rapport, demonstrates 
empathy). Competence scores sessions were high in both the UP (mean: 4.44 out of 5) and SDP 
(mean: 4.09 out of 5) conditions. 
Measures 
 In order to provide a comprehensive understanding of the UP’s effects on depression, the 
present study includes three unique indicators of this condition. These measures are, of course, 
related, though correlations (r = .55 - .61) suggest they are not entirely overlapping (Bentley, 
Gallagher, Carl, & Barlow, 2014; Gallagher et al., 2013) 
Diagnostic assessment. Blinded study evaluators used a semi-structured clinical 
interview, the Anxiety Disorders Interview Schedule (ADIS; Brown & Barlow, 2014; DiNardo et 
al., 1994), to assess patients for current DSM diagnoses. Diagnoses are assigned a clinical 
severity rating (CSR) on a scale from 0 to 8; ratings of 4 or above indicate that a patient meets 
clinical threshold for the diagnosed disorder and, as noted previously, individuals with ratings 
above 4 for any depressive disorder were included in the present study. ADIS CSR scores 
represent clinician impressions of overall distress and impaired experienced as a function of a 
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particular mental health conditions. These ratings are transdiagnostic (i.e., are on the same scale 
across disorders assessed by the ADIS), allowing us to explore changes in CSR for MDD 
specifically, as well as for any depressive disorder. As reported in the parent trial, inter-rater 
agreement was 98% for principal diagnosis ADIS CSR, following criteria specified by Brown et 
al., (2001).  
Clinician-rated. The Hamilton Depression Rating Scale (HAM-D; Hamilton, 1960) is a 
17-item widely used measure of depressive symptoms administered by independent evaluators in 
accordance with the Structured Interview Guide for the Hamilton Depression Rating Scale 
(SIGH-D; Williams, 1988). In the present study, HAM-D scores represent clinician-rated 
impressions of symptom severity. The measure includes one item (item 11) evaluating suicidal 
thoughts and behaviors, made up of the following questions “This past week, have you had any 
thoughts that life is not worth living, or that you would be better off dead?,” “What about having 
thoughts of hurting or even killing yourself?,” and “Have you actually done anything to hurt 
yourself?” Responses are categorized in terms of severity from 0-6 (0 = absent, 1 = feels life is 
not worth living, 2 = wishes to be dead or has any thoughts of possible death to self, 3 = suicidal 
ideas or gestures, 4 = attempts at suicide). As reported in the parent trial, inter-rater agreement 
for the HAM-D was 0.92.  
Self-report. The Overall Depression Severity and Impairment Scale (ODSIS; Bentley, 
Gallagher, Carl, & Barlow, 2014) is a measure adapted from the Overall Anxiety Severity and 
Impairment Scale (OASIS; Norman, Hami Cissell, Means-Christensen, & Stein, 2006) to briefly 
assess depression severity and impairment. The ODSIS asks about depressive symptoms in the 
past week, and scores range from 0 to 20 with a clinical cutoff of 8. The ODSIS has established 
good internal consistency, convergent validity, and discriminant validity (Bentley et al., 2014). 
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In this sample, a = .87 at baseline. 
Results 
 With regard to depressive diagnoses, across the three treatment conditions, 31 patients 
met criteria for major depressive disorder, 12 met criteria for dysthymia (DSM-IV) or persistent 
depressive disorder (DSM-5), 6 met criteria for not-otherwise specified depressive disorder 
(DSM-IV)/other specified depressive disorder (DSM-5). In several instances, individuals met 
criteria for more than one depressive disorder; thus the number of discrete depressive disorders 
exceeded the total N. See Table 1 for a breakdown of depressive diagnoses with each principal 
anxiety disorder category included in the parent study, along with as a function of treatment 
condition. The mean CSR at baseline for any depressive disorder in this sample was 4.61, 
suggesting moderate symptoms and interference. Additionally, there were no significant 
differences in CSR (Hedge’s g = 0.30, [-0.39,0.99]), HAM-D ratings (Hedge’s g = 0.44, [-0.31, 
1.19]), or ODSIS (Hedges’s g = 0.73, [-0.16, 1.62]) scores at baseline between patients in UP 
and WLC conditions at baseline. Similarly, there were no pre-treatment differences in depression 
scores between the UP and SDP in CSR (Hedge’s g = -.16, [-1.02, .71]), HAM-D ratings 
(Hedge’s g = 0.31, [-0.39,1.01]), or ODSIS (Hedges’s g = 0.55, [-0.16, 1.26]).  
 Descriptive data and within condition effect sizes for the UP, WLC, and SDP conditions 
at all available time points can be viewed in Table 2. Means for all depression variables changed 
in the expected direction across treatment with the UP; specifically, mean CSR (for any 
depressive disorder and MDD, in particular), HAM-D ratings, and ODSIS scores decreased from 
baseline to post-treatment, and continued improvement was observed at the 12-month follow-up 
assessment. Within-condition standardized mean gain effect sizes (ESsg) revealed that these 
changes from baseline to the 12-month follow-up were large in magnitude and statistically 
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significant (indicated by confidence intervals not overlapping zero) in the UP.  
In contrast, across CSRs, HAM-D ratings, and ODSIS scores, depressive symptoms did 
not improve significantly for WLC from pre- to post-treatment. Between-condition effect sizes 
comparing patients in the UP and WLC conditions at post-treatment revealed significant 
differences in HAM-D ratings favoring the UP that were large in magnitude (Hedge’s g = -1.11, 
[-2.07, -0.15]). Medium to large differences were also observed between UP and WLC 
conditions for CSRs (any depressive disorder; Hedge’s g = -0.77, [-1.64, 0.09]) and ODSIS 
scores (Hedge’s g = -1.07, [-2.17, 0.03]) at post-treatment, though these effects only approached 
significance.  
 Means across study time-points, along with within-condition effect sizes, revealed that 
the SDP condition exhibited a similar pattern of change in depressive symptoms to the UP 
condition; specifically, SDP patients demonstrated statistically significant improvements in 
clinician-rated and self-reported symptoms of depression, that were large in magnitude; changes 
in diagnostic severity (i.e., ADIS CSR) were not statistically significant (though they were in the 
UP condition). Additionally, there were no statistically significant differences in CSR for any 
depressive disorder (Hedge’s g = 0.48, [-0.37, 1.33]), HAM-D ratings (Hedge’s g = 0.28, [-0.56, 
1.12]), or ODSIS (Hedges’s g = 0.30, [-0.57, 1.17]) between the UP and SDP conditions at post-
treatment or at the 12-month follow-up assessment (CSR: Hedge’s g = .43, [-1.39, 1.24]; HAM-
D: Hedge’s g = 0.31, [-0.34,1.24]; ODSIS: Hedges’s g = 0.26, [-0.56, 1.08]). 
 Additionally, a more in-depth investigation on the effect of the UP on suicidal ideation 
(as a core symptom of depression) was conducted. Specifically, we examined the frequency of 
non-zero responses to item 11 on the HAM-D. In the UP condition, 8 individuals endorsed a 
value of at least one on this item at baseline; scores ranged from 1 to 3, indicating that suicidal 
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ideation in our sample ranged from beliefs that life is not worth living (n = 6), to thoughts of 
death and dying (n = 1), to intent and/or an expressed plan (n = 1). At post-treatment, one 
individual reported feeling that life is not worth living (i.e., score of 1 on HAM-D item 11), and 
at the 12-month follow-up, no patients endorsed this item. Similarly, in the SDP condition, four 
individuals endorsed a value of one (beliefs that life is not worth living) on this item at baseline. 
At post-treatment, one individual reported feeling that life is not worth living (i.e., score of 1 on 
HAM-D item 11), and at the 12-month follow-up, no patients endorsed this item. In contrast, in 
the WLC condition, 2 individuals expressed feelings that life is not worth living at baseline, 
whereas 1 patient responded this way at the end of the waitlist period. Given the low base rate 
for these responses, subsequent statistical tests were not conducted. In summary, however, within 
both the UP and SDP conditions, the frequency and severity of suicidal item endorsement 
decreased in the expected direction across treatment and into the follow-up phase.  
Discussion 
The current study explored the effects of treatment with the UP on depressive symptoms 
and suicidal ideation for patients with a principal anxiety disorder who also met criteria for at 
least one unipolar depressive disorder. Results suggest that individuals who received the UP 
experienced large reductions in symptoms of depression (across clinician-rated and self-report 
measures) both at the end of treatment and one year following care, compared to baseline levels. 
Furthermore, descriptive statistics suggest that participants with suicidal ideation (defined as a 
non-zero response on item 11 of the HAM-D) showed reductions in these symptoms following 
treatment that were maintained one year later.  
Moreover, patients who received the UP experienced significantly lower levels of 
depressive symptoms at post-treatment when compared to participants on the waitlist on one 
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clinician-rated measure of depressive severity (i.e., HAM-D). Differences in depressive 
symptoms between the treatment and control groups trended toward significant at the end of 
treatment on the other two measures included in the study (i.e., ADIS CSR and ODSIS), likely 
due to the small sample size. As an exploratory aim, we sought to compare effects on depressive 
symptoms between the UP and gold standard SDPs for anxiety disorders; results suggest that 
SDP patients demonstrated similar improvements to individuals in the UP condition (though 
diagnostic severity ratings were greater in magnitude in the UP condition), and clinician-rated 
and self-reported depression scores were not significantly different as a function of condition at 
post-treatment or at the 6-month follow-up assessment. 
Findings from the present study align with prior research on the effects of transdiagnostic 
treatments on symptoms of depression and suicidal ideation (Bentley et al., 2017b; Ellard et al., 
2010; Farchione et al., 2012; Norton, Hayes, & Hope, 2004). These results provide further 
support that the UP may improve depressive symptoms in individuals with heterogenous anxiety 
disorders (Ellard et al., 2010; Farchione et al., 2012). Additionally, consistent with findings from 
the full sample (Barlow et al., 2017), we found that UP resulted in similar symptom reduction as 
the SDPs in individuals who met criteria for a depressive disorder. Beyond clinical 
improvements, transdiagnostic interventions like the UP, may confer dissemination advantages 
as clinicians need only learn one protocol that is broadly applicable to the majority of their 
patients (McHugh, Murray, & Barlow, 2009). Additionally, lower attrition rates in the UP 
compared to the SDP condition (Barlow et al., 2017) suggest that transdiagnostic interventions 
may also be more acceptable to patients with comorbid psychopathology. 
Limitations 
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 The conclusions from the current study must be interpreted in the context of its 
limitations. The present sample was drawn from a study recruiting patients with principal anxiety 
disorders, which posed two challenges. First, the number of individuals with a depressive 
disorder was relatively small, resulting in a sample that was underpowered to compare the two 
active treatment conditions (UP and SDP). Additionally, all participants met criteria for a 
principal anxiety disorder, limiting our ability to generalize our findings to patients with 
principal depression; epidemiological data, however, suggests that rates of co-occurrence 
between anxiety and depressive disorders are quite high (e.g., Kessler, 1996). Further limiting 
generalizability, our sample was predominately Caucasian and college educated, reflecting 
demographics of our Center; future research should be conducted that includes individuals from 
diverse racial, ethnic, and socioeconomic backgrounds. Finally, full analyses were not conducted 
on the occurrence of suicidal ideation in the sample due to low base rates of these experiences 
among participants.  
Clinical Implications and Future Directions 
 The UP offers a transdiagnostic, streamlined approach to the treatment of emotional 
disorders, and may allow for more effective dissemination of empirically-supported treatments to 
more clinicians, and in turn provide greater access to these services for patients. Future studies 
evaluating transdiagnostic CBT for treatment of depression are needed in larger, more diverse 
(e.g., severity of clinical presentation, race/ethnicity, socioeconomic status, education) samples 
of individuals. Additionally, future research should actively recruit individuals presenting with 
principal depression and clinically significant suicidal thoughts to participate in randomized-
controlled trials comparing the UP to existing treatments.   
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Table 1. Breakdown of Depressive Disorder Occurrence within Principal Anxiety Diagnoses 
 Principal Anxiety Disorder 
Depressive Diagnosis PD/A SOC GAD OCD 
      MDD 
UP     n = 12 
SDP   n =  9 
WLC  n = 10   
Total   n = 31 
 
 
n = 2 
n = 1 
n = 1 
n = 4 
 
n = 5 
n = 2 
n = 2 
n = 9 
 
n = 4 
n = 5 
n = 5 
n = 14 
 
n = 1 
n = 1 
n = 2 
n = 4 
   PDD/DYS 
UP     n = 7 
SDP   n =  2 
WLC  n = 3  
Total   n = 12 
 
 
n = 1 
n = 1 
n = 0 
n = 2 
 
n = 1 
n = 1 
n = 1 
n = 3 
 
n = 1 
n = 0 
n = 0 
n = 1 
 
n = 4 
n = 0 
n = 2 
n = 6 
Total DDNOS/OS DD 
UP     n = 1 
SDP   n =  4 
WLC  n = 1   
Total   n = 6 
 
 
n = 0 
n = 1 
n = 0 
n = 1 
 
n = 0 
n = 2 
n = 0 
n = 2 
 
n = 0 
n = 0 
n = 1 
n = 1 
 
n = 1 
n = 1 
n = 0 
n = 2 
 Note: PD/A = Panic disorder with/or without agoraphobia, SOC = social anxiety disorder, GAD = 
generalized anxiety disorder, OCD = obsessive compulsive disorder, MDD = major depressive 
disorder, PDD = persistent depressive disorder, DYS = dysthymia, DDNOS = not-otherwise 
specified depressive disorder, and OS DD = other specified depressive disorder. UP = Unified 
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Table 2. Means and Within-condition Effect Sizes at All Available Study Timepoints	
Note: MDD_CSR = The clinical severity rating from the Anxiety Disorders Interview Schedule 
(ADIS) for major depressive disorder; Any DD_CSR = The ADIS clinical severity rating for any 
depressive disorder; HAM-D = Hamilton Rating Scale for Depression; ODSIS = Overall 
Depression Severity and Interference Scale; UP = Unified Protocol; SDP = Single Diagnosis 









Change Pre Post 12MFU 
MDD CSR 
UP M=4.58 M=2.63 M=1.63 ESsg=1.63(large) ESsg=3.29(large) 
n=12 n=8 n=8 CI[0.42,2.83] CI[1.39,5.18] 
SD=0.51 SD=1.60 SD=1.19     
SDP M=4.67 M=2.20 M=2.00 ESsg=1.50(large) ESsg=1.76(large) 
n=9 n=5 n=6 CI[-0.09,3.09]  CI[-0.01,3.53] 
SD=0.50 SD=2.05 SD=2.19   
WLC M=4.60 M=4.33  ESsg=0.34(small)   
n=10 n=6  CI[-0.15,0.82]   
SD=0.70 SD=1.37      
Any DD 
CSR 
UP M=4.70 M=2.93 M=2.08 ESsg=1.60(large) ESsg=2.62(large) 
n=20 n=14 n=13 CI[0.73,2.48] CI[1.36,3.88] 
SD=0.66 SD=1.38 SD=1.32     
SDP M=4.36 M=2.11 M=1.36 ESsg=1.68(large) ESsg=2.36(large) 
n=14 n=9 n=11 CI[0.49,2.86]  CI[0.88,3.83] 
SD=1.34 SD=1.96 SD=1.91   
WLC M=4.50 M=4.11  ESsg=0.35 (small)   
n=14 n=9  CI [-0.19, 0.89]   
SD=0.65 SD=1.62      
HAM-D 
UP M=19.59 M=8.61 M=7.75 ESsg=1.72 (large) ESsg=1.43 (large) 
n=17 n=12 n=12 CI [0.68, 2.76] CI [0.50, 2.37] 
SD=7.27 SD=6.52 SD=7.36     
SDP M=17.40 M=6.76 M=4.92 ESsg=1.53(large) ESsg=1.99(large) 
n=15 n=10 n=11 CI[0.59,2.47]  CI[0.85,3.13] 
SD=6.40 SD=6.21 SD=5.75   
WLC M=16.74 M=15.50  ESsg=0.03 (small)   
n=12 n=8  CI [-0.76, 0.82]   
SD=4.47 SD=4.87      
ODSIS 
UP M=13.83 M=5.67 M=3.44 ESsg=2.22(large) ESsg=2.28(large) 
n=12 n=9 n=9 CI[1.04,3.40] CI[1.13,3.44] 
SD=3.71 SD=3.39 SD=4.80     
SDP M=11.33 M=4.22 M=2.64 ESsg=2.00(large) ESsg=2.41(large) 
n=15 n=9 n=11 CI[0.73,3.26]  CI[1.14,3.68] 
SD=4.13 SD=3.87 SD=3.67   
WLC M=10.78 M=10.33  ESsg=0.57(medium)   
n=9 n=6  CI[-0.06,1.19]   
SD=4.41 SD=5.05      
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Figure Captions 
 
1a. Average clinical severity ratings (CSR) for major depressive disorder as a function of condition 
at each timepoint. Pre = Pre-treatment, Post = Post-treatment, 12MFU = 12-month follow-up 
assessment. UP = Unified Protocol, SDP = Single Disorder Protocol, WLC = Waitlist control 
condition. 
 
1b. Average Hamilton Anxiety (HAM-A) ratings as a function of condition at each timepoint. Pre 
= Pre-treatment, Post = Post-treatment, 12MFU = 12-month follow-up assessment. UP = Unified 
Protocol, SDP = Single Disorder Protocol, WLC = Waitlist control condition. 
 
1c. Average Overall Depression Severity and Impairment Scale (ODSIS) scores as a function of 
condition at each timepoint. Pre = Pre-treatment, Post = Post-treatment, 12MFU = 12-month 
follow-up assessment. UP = Unified Protocol, SDP = Single Disorder Protocol, WLC = Waitlist 
control condition. 
 
